

IN THE SPECIFICATION:

Please amend the paragraph on page 1, lines 5-9, as follows:

This application is continuation-in-part of U.S. Application Serial No. 09/911,777, filed July 24, 2001, which claims priority to International Application No. PCT/US00/01788 filed January 25, 2000, which claims priority to U.S.S.N. 60/117,169 filed on January 25, 1999 and U.S.S.N. 60/143,228 filed July 9, 19992000. The entire disclosures of the aforesaid patent applications are incorporated herein by reference.

Please the paragraph on page 32, lines 1-16, as follows:

B cell growth was efficiently costimulated with recombinant soluble BAFF lacking the transmembrane domain. This activity is in contrast to several TNF family members which are active only as membrane-bound ligand such as TRAIL, FasL and CD40L. Soluble forms of these ligands have poor biological activity which can be enhanced by their cross-linking, thereby mimicking the membrane-bound ligand (15). In contrast, cross-linking Flag-tagged sBAFF with anti-FLAG antibodies or the use of membrane-bound BAFF expressed on the surface of epithelial cells did not further enhance the mitogenic activity of BAFF, suggesting that it can act systemically as a secreted cytokine, like TNF does. This is in agreement with the observation that a polybasic sequence present in the stalk of BAFF acted as a

substrate for a protease. Similar polybasic sequences are also present at corresponding locations in both APRIL and TWEAK and for both of them there is evidence of proteolytic processing (30) (N.H. and J.T, unpublished observation). Although the protease responsible for the cleavage remains to be determined, it is unlikely to be the metalloproteinase responsible for the release of membrane-bound TNF as their sequence preferences differ completely (21). The multibasic motifs in BAFF (R-N-K-R) (SEQ ID NO:23), APRIL (R-K-R-R) (SEQ ID NO:24) and Tweak (R-P-R-R) (SEQ ID NO:25) are reminiscent of the minimal cleavage signal for furin (R-X-K/R-R) (SEQ ID NO:26), the prototype of a proprotein convertase family (31).

Please amend the paragraph on page 17, lines 4-7, as follows:

“BAFF receptors” have been identified and characterized and include TACI (see, e.g., U.S. Pat. No. 5,969,102 and WO98/39361, incorporated herein by reference), BCMA (see, e.g., WO01/12812, incorporated herein by reference), and BAFFR (e.g., GenBank™ accession No. AF373846 for human BAFF-R (SEQ ID NO:27) and accession No. AF373847 for murine BAFF-R (SEQ ID NO:28); see, also, e.g., Thompson et al. (2001) Science 293:2108, incorporated herein by reference).

IN THE SEQUENCE LISTING:

Please replace the Sequence Listing (both the paper and electronic versions)
with the attached Sequence Listing.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

IN THE DRAWINGS:

Please replace Figures 1A, 1B, 1C, 2A, 2B, and 6 with the attached replacement sheets for respective Figures.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com